PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability

Christina Fevga1, Christelle Tesson2, Ana Carreras Mascaro1

  • 1Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands.

Insights

New genetic variants in the PTPA gene cause early-onset parkinsonism and intellectual disability by impairing protein phosphatase 2A (PP2A) activation. These findings highlight PP2A

Area of Science:

  • Neurogenetics
  • Molecular Neuroscience
  • Biochemistry

Background:

  • Protein phosphatase 2A (PP2A) is a key Ser/Thr phosphatase in the brain, regulating neurodegeneration-associated proteins like alpha-synuclein, tau, and LRRK2.
  • PP2A plays critical roles in various signaling pathways and cellular functions within the central nervous system.

Purpose of the Study:

  • To identify the genetic cause of early-onset parkinsonism and intellectual disability in two families.
  • To investigate the functional consequences of identified genetic variants on PP2A complex activity and neurodegenerative pathways.

Main Methods:

  • Clinical evaluation and genetic analyses including genome-wide linkage analysis, whole-exome sequencing, and Sanger sequencing.
  • Functional studies in cultured cells and Drosophila melanogaster models to assess variant effects on PTPA and PP2A.
  • Assessment of motor symptoms and response to treatments like levodopa and deep brain stimulation.

Main Results:

  • Identified homozygous PTPA variants (p.Met298Arg and p.Ala171Asp) co-segregating with disease in affected families.
  • Both variants led to decreased PTPA RNA and protein stability, reduced PP2A complex levels, and impaired PP2A phosphatase activation.
  • Knock-down of PTPA in Drosophila neurons caused locomotion deficits, which were reversed by L-DOPA treatment.

Conclusions:

  • Bi-allelic missense PTPA variants impairing PP2A activation cause autosomal recessive early-onset parkinsonism with intellectual disability.
  • The study provides insights into the role of the PP2A complex in neurodegeneration pathogenesis.
  • Therapeutic strategies targeting PP2A may offer potential for treating parkinsonism and related neurodegenerative disorders.